La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Scinai Immunotherapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Scinai Immunotherapeutics..

Scinai Immunotherapeutics (NASDAQ:SCNI) Azioni, Catena delle Opzioni

Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics Ltd

Small Cap

Press Releases

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Earnings

Scinai Announces Annual Financial Results for 2024

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

SCNI

Aditxt

Aptevo Therapeutics

Azitra

Bone Biologics

BriaCell Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Bio Green Med Solution, Inc. - 6% Convertible Preferred Stock

Bio Green Med Solution

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

ETHZilla

GRI Bio

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Liminatus Pharma

Medicus Pharma

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Soligenix

Alaunos Therapeutics, Inc. - Common Stock

Comments

Scinai Immunotherapeutics

Scinai Immunotherapeutics (SCNI) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO